MedTrace Logo

Behavioral Effects of Drugs: Inpatient (35)

NCT03519022 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-06-25

No results posted yet for this study

Summary

This study will determine the influence of methylphenidate (Metadate®) and duloxetine (Cymbalta®), alone and in combination, on the reinforcing, subjective and physiological effects of cocaine.

Conditions

  • Cocaine Use Disorder

Interventions

DRUG

Cocaine

The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.

DRUG

Placebo oral capsule

The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.

DRUG

Methylphenidate

The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Craig Rush

    lead OTHER

Principal Investigators

  • Craig R Rush, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-05-31
Completion
2019-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03519022 on ClinicalTrials.gov